- Home
- CRVS vs LENZ Comparison
CRVS vs LENZ Comparison
Compare CRVS & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVS | LENZ |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 546.7M | 609.5M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRVS | LENZ |
|---|---|---|
| Price | $25.23 | $20.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $28.00 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 6.7M | 1.1M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $203.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $14.43 |
| 52 Week High | $26.22 | $50.40 |
Technical Indicators
Market Signals| Indicator | CRVS | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 91.48 | 55.66 |
| Support Level | $6.46 | $19.02 |
| Resistance Level | $7.18 | $21.80 |
| Average True Range (ATR) | 1.66 | 1.43 |
| MACD | 2.20 | 0.91 |
| Stochastic Oscillator | 91.63 | 80.33 |
Price Performance
Historical ComparisonAbout CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.